Internal Server Error

Brii Biosciences - About the company

Brii Biosciences is a public company based in San Francisco (United States), founded in 2018 by Zhi Hong. It operates as a Developer of biologics to treat hepatitis B infection. Brii Biosciences has raised $415M in funding from investors like Invesco, Arch Venture Partners and Yunfeng Capital. The company has 388 active competitors, including 107 funded and 95 that have exited. Its top competitors include companies like HOOKIPA Pharma, Atea and ImmunityBio.

Company Details

Developer of biologics to treat hepatitis B infection. It has clinical programs focused on hepatitis B virus (HBV) infection and immunotherapeutics to treat infectious diseases. It has licensed rights to develop a recombinant protein-based immunotherapeutic (VBI-2601) from VBI Vaccines in China. It is also developing VIR-2218, an investigational RNA interference (RNAi) therapeutics to treat hepatitis B infection (licensed from Vir Biotechnology).
Email ID
*****@briibio.com
Registered Address
Durham, North Carolina
Key Metrics
Founded Year
2018
Location
San Francisco, United States
Stage
Public
Total Funding
$415M in 3 rounds
Latest Funding Round
Investors
Ranked
Employee Count
84 as on Sep 30, 2026
Investment & Acquisitions
Similar Companies
Exit Details
Public

Brii Biosciences's IPO details

Brii Biosciences got listed on Jul 13, 2021.
Click here to take a look at Brii Biosciences's IPO in detail
Sign up to download Brii Biosciences' company profile

Brii Biosciences's funding and investors

Brii Biosciences has raised a total funding of $415M over 3 rounds. Its first funding round was on May 25, 2018. Brii Biosciences has 9 institutional investors.

Here is the list of recent funding rounds of Brii Biosciences:
Date of Funding
Funding Amount
Round Name
Post-Money Valuation
Revenue Multiple
Lead Investors
Other Investors
Sep 07, 2021
8456835
Post IPO
7440066
8633795
9109904
7778899
Mar 23, 2021
2484068
Series D
2856364
5924178
3622313
May 25, 2018
8576046
Series D
1516413
4325858
7864492
lockAccess funding benchmarks and valuations. Sign up today!

Brii Biosciences' founders and board of directors

Founder? Claim Profile
The founders of Brii Biosciences is Zhi Hong. Zhi Hong is the CEO of Brii Biosciences.
Here are the details of Brii Biosciences' key team members:
  • Zhi Hong: Co-Founder & CEO of Brii Biosciences.

Brii Biosciences' employee count trend

Brii Biosciences has 84 employees as of Sep 26. Here is Brii Biosciences's employee count trend over the years:
Employee count trend for Brii Biosciences
lockUncover Brii Biosciences' growth story! Sign up today!
chrome_extension_cta_illustration
Access Tracxn on any website
Our Google Chrome extension lets you view company details while browsing their websites
Install Tracxn Extension

Brii Biosciences's Competitors and alternates

Top competitors of Brii Biosciences include HOOKIPA Pharma, Atea and ImmunityBio. Here is the list of Top 10 competitors of Brii Biosciences, ranked by Tracxn score:
Rank
Company Details
Short Description
Total Funding
Investors
Tracxn Score
1st
Logo for HOOKIPA Pharma
HOOKIPA Pharma
2011, Vienna (Austria), Public
Developer of immunotherapies for the treatment of infectious diseases and cancer
$134M
70/100
2nd
Logo for Atea
Atea
2014, Boston (United States), Public
Developer of therapeutics for viral diseases
$293M
67/100
3rd
Logo for ImmunityBio
ImmunityBio
2014, El Segundo (United States), Public
Developer of peptide-based vaccines for immunotherapy
$169M
67/100
4th
Logo for Vaxart
Vaxart
2004, San Francisco (United States), Public
Developer of therapeutic solutions for treating multiple infectious diseases
$58M
67/100
5th
Logo for Tonix Pharma
Tonix Pharma
2007, New York City (United States), Public
Developer of next-generation medicines for CNS and immunological disorders
$4.45M
66/100
6th
Logo for Brii Biosciences
Brii Biosciences
2018, San Francisco (United States), Public
Developer of biologics to treat hepatitis B infection
$415M
63/100
7th
Logo for Osivax
Osivax
2017, Lyon (France), Series B
Developer of vaccines against constantly mutating pathogens
$42.2M
63/100
8th
Logo for Leyden Labs
Leyden Labs
2020, Leiden (Netherlands), Series B
Developer of nasal sprays containing antibodies targeting respiratory viruses in the nasal mucosa
$303M
63/100
9th
Logo for Ascletis Pharma
Ascletis Pharma
2011, Hangzhou (China), Public
Developer of small molecules for the treatment of multiple diseases
$255M
62/100
10th
Logo for eradivir
eradivir
2020, West Lafayette (United States), Series A
Developer of immunotherapies for the treatment of infectious diseases
$20.4M
62/100
lockGet insights and benchmarks for competitors of 2M+ companies! Sign up today!
Looking for more details on Brii Biosciences's competitors? Click here to see the top ones

Brii Biosciences's Investments and acquisitions

Brii Biosciences has a total of 1 investment in AN2 Therapeutics. Brii Biosciences has not made any acquisitions as of now.

Reports related to Brii Biosciences

Here is the latest report on Brii Biosciences's sector:

News related to Brii Biosciences

lockFilter this list
Media has covered Brii Biosciences for a total of 6 events in the last 1 year, 3 of them have been about company updates and 1 about people movement.
•
•
Durham firm acquires hepatitis B drug from defunct companyThe Business Journals•Jan 02, 2025•Brii Biosciences
lockGet curated news about company updates, funding rounds, M&A deals and others. Sign up today!

FAQs about Brii Biosciences

Explore our recently published companies
  • Way - Helsinki based, 2024 founded, Seed company
  • Delite - Hyderabad based, 2010 founded, Unfunded company
  • Yuki - Tel Aviv based, 2023 founded, Seed company
Tracxn powers 1,000+ customers across 30+ countries
Accel PartnersPartechIN-Q-TEL - USFujitsuTenityStanford